<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00347360</url>
  </required_header>
  <id_info>
    <org_study_id>CFD105453</org_study_id>
    <nct_id>NCT00347360</nct_id>
  </id_info>
  <brief_title>The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial</brief_title>
  <official_title>A Randomized, Double-Blind, Double-Dummy, Parallel Group, Factorial Design Trial to Assess the Efficacy and Safety of up to Six Weeks Treatment With 20mg, 40mg, or 80mg QD Doses of Carvedilol Controlled Release Formulation (COREG CR) or 10mg, 20mg, or 40mg QD Doses of Lisinopril (Zestril) or a Combination of One of the Doses of Each Medication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, double-dummy, parallel group trial employing 15 cells of
      a 4x4 factorial design (no placebo)to compare the hypertensive effects in patients with Stage
      1 and Stage 2 hypertension of carvedilol (20, 40 or 80 mg daily) alone, lisinopril (10, 20 or
      40 mg daily) alone, and all combinations of the doses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Double-Blind, Double-Dummy, Parallel Group, Factorial Design Trial to Assess
      the Efficacy and Safety of up to Six Weeks Treatment with 20mg, 40mg, or 80mg QD Doses of
      Carvedilol Controlled Release Formulation (COREG CR) or 10mg, 20mg, or 40mg QD Doses of
      Lisinopril (ZESTRIL) or a Combination of One of the Doses of Each Medication
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Week 6 in 24 Hour (hr) Mean Diastolic Blood Pressure</measure>
    <time_frame>Baseline, Week 6.</time_frame>
    <description>Ambulatory blood pressure monitoring (ABPM) was completed at Baseline and at the end of treatment/Week 6 or early withdrawal by standard electronic ABPM equipment worn by the subject for 24-hr of ambulatory activity. The 24 hr assessment period started at the time of the first reading and ended exactly 24 hr later on the following day. Data collected included mean diastolic blood pressure (DBP).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to Week 6 in Trough Diastolic Blood Pressure</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Trough ABPM was the average across 20-24 hr after dosing for each subject.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 6 in 24 Hour Mean Systolic Blood Pressure</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Ambulatory blood pressure monitoring (ABPM) was completed at Baseline and at the end of treatment/Week 6 or early withdrawal by standard electronic ABPM equipment worn by the subject for 24-hr of ambulatory activity. The 24 hr assessment period started at the time of the first reading and ended exactly 24 hr later on the following day. Data collected included mean systolic blood pressure (SBP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 6 in Trough Systolic Blood Pressure</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Trough ABPM was the average across 20-24 hr after dosing for each subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-response Treatment Estimates: Change From Baseline to Week 6 in 24 Hour Mean DBP by ABPM (Ambulatory Blood Pressure Monitoring)</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Evaluation of the dose-response relationship between incremental doses of carvedilol CR and lisinopril and mean 24-hr ABPM DBP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 6 in Trough to Peak Ratios of DBP by 24 Hour ABPM (Ambulatory Blood Pressure Monitoring)</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Trough (20-24 hr) to peak (3-7 hr) ratios of DBP were examined in order to evaluate the extent to which once-daily criteria were met (ie trough:peak &gt; 50%). Trough to peak ratios were calculated from change trough mean/change peak mean x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Description of Safety in Each Treatment Group Using Adverse Events, Laboratory Evaluations, ECG Changes, Vital Sign Changes, and Withdrawal Rates.</measure>
    <time_frame>Weeks 1 through 48</time_frame>
    <description>Refer to Adverse Event section for safety information.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 6 in Mean SBP and DBP Measured in Morning by 24 Hour ABPM</measure>
    <time_frame>Morning BP, Baseline, Week 6</time_frame>
    <description>Mean changes from Baseline to Week 6 in DBP and SBP measured by 24hr ABPM at the end of up-titration recorded in the morning. The morning assessment period started at or after 6 am and ended immediately before 12 noon.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 6 in Mean SBP and DBP Measured in Afternoon by 24hr ABPM</measure>
    <time_frame>Afternoon BP, Baseline, Week 6</time_frame>
    <description>Mean changes from Baseline to Week 6 in SBP and DBP measured by 24hr ABPM at the end of up-titration recorded in the afternoon. The afternoon assessment period started at or after 12 noon and ended immediately before 6 pm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 6 in Mean SBP and DBP Measured at Night by 24hr ABPM</measure>
    <time_frame>Night BP, Baseline, Week 6</time_frame>
    <description>Mean changes from Baseline to Week 6 in DBP and SBP measured by 24hr ABPM at the end of up-titration recorded in the night. The night-time assessment period started at the time of the first reading at or after 6 pm and ended immediately before 6 am on the following day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 6 in Mean Trough Sitting SBP and Sitting DBP by Cuff Assessment</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Analysis of Change from Baseline to Week 6 in Mean sSBP and sDBP by Cuff Assessments at Drug Trough (20-24 hr) at End of Treatment Titration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Responders, Defined as â‰¥ 10 mmHg Sitting (s)DBP Reduction From Baseline or a sDBP of &lt;90 / 80 Millimeters (mm) of Mercury (Hg) for Non Diabetic / Diabetic Subjects Respectively (Based on Cuff Trough Measures)</measure>
    <time_frame>Week 6</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">654</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>lisinopril</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lisinopril</description>
  </arm_group>
  <arm_group>
    <arm_group_label>carvedilol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>carvedilol controlled release formulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lisinopril</intervention_name>
    <arm_group_label>lisinopril</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carvedilol controlled release formulation</intervention_name>
    <arm_group_label>carvedilol</arm_group_label>
    <other_name>lisinopril</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has given signed informed consent.

          -  Subject is male or female 18 years of age at the time informed consent is signed.

          -  At the Screening visit, subject has a documented history or current presentation with
             stage 1 or stage 2 hypertension (see Section 15.1, Appendix 1 and Section 15.4,
             Appendix 4) which meets one of the following criteria. Note: All blood pressures are
             mean sitting cuff pressures:

        Documented history of hypertension and receiving two antihypertensive medications with mean
        sDBP &lt;90 mmHg or for diabetic subjects (defined as having an established diagnosis of
        diabetes or receiving treatment for diabetes), mean sDBP &lt;80 mmHg. Subjects taking beta
        blockers, clonidine, or other antihypertensive medications where abrupt discontinuation
        would be of clinical concern must be tapered off the medication during the Washout/Placebo
        Run-in phase to avoid rebound hypertension. All subjects must be able to be safely
        withdrawn from all antihypertensive treatment during the Washout/Placebo Run-in phase.
        Subjects should not be enrolled if the investigator thinks it is likely the subject's mean
        sDBP will exceed 109 mmHg or their mean sSBP will exceed 180 mmHg during the
        Washout/Placebo Run-in phase (NOTE: A combination drug containing two antihypertensive
        agents represents two antihypertensive medications [e.g., Hyzaar is losartan potassium AND
        hydrochlorothiazide, therefore, counts as two antihypertensive medications].) OR Receiving
        one antihypertensive medication with mean sDBP =109 mmHg and can be safely withdrawn from
        all antihypertensive medication during the Washout/Placebo Run-in phase. Any subject who is
        receiving beta-blockers, clonidine, or other antihypertensive medications where abrupt
        discontinuation would be of clinical concern must have the dose tapered down during the
        Washout/Placebo Run-in phase to avoid rebound hypertension. All subjects must be able to be
        safely withdrawn from all antihypertensive treatment during the Washout/Placebo Run-in
        phase. Subjects should not be enrolled if the investigator thinks it is likely the
        subject's mean sDBP will exceed 109 mmHg or their mean sSBP will exceed 180 mmHg during the
        Washout/Placebo Run-in phase.

        (NOTE: A combination drug containing two antihypertensive agents represents two
        antihypertensive medications [e.g., Hyzaar is losartan potassium AND hydrochlorothiazide,
        therefore, counts as two antihypertensive medications].

        OR Untreated/newly diagnosed subjects: mean sDBP =95 and =109, or for diabetic subjects,
        mean sDBP =85 and =109 (see Section 15.1, Appendix 1). If newly diagnosed, must have
        qualifying blood pressure confirmed on two consecutive visits with the mean sDBP value not
        differing more than 8 mmHg. (Previously untreated subjects include subjects who have not
        been treated for hypertension in the last two months.).

          -  At Baseline:

        DAY BEFORE RANDOMIZATION: Prior to having the baseline ABPM equipment placed, subject has
        mean sitting cuff DBP that is â‰¥93 and â‰¤111 mmHg (or for diabetic subjects, â‰¥83 and â‰¤111
        mmHg). Subjects who were taking antihypertensive medication at Screening and do not meet
        this criterion after one week (or 5 half-lives, whichever is longer), can return in one
        week Â±1day and have his/her blood pressure evaluated again for this inclusion criterion.

        AND

        RANDOMIZATON DAY: After completion of the ABPM assessment, subject meets the following ABPM
        (both 12 hr and 24 hr) criteria (see Section 15.1, Appendix 1):

          -  Mean 12-hour daytime (9 AM to 9 PM) DBP â‰¥90 and â‰¤109mmHg (or for diabetic subjects,
             â‰¥80 and â‰¤109mmHg)

          -  At least 75% of the programmed readings properly recorded over 24-hour monitoring
             period

          -  No more than two non-consecutive hours with less than two successful readings per hour
             while awake, and no more than two consecutive hours with less than one successful
             reading per hour during the sleep period over the 24-hour monitoring period

          -  At least two successful readings per hour for three of the last four hours of
             recording (trough period i.e., 20-24 hour during which subjects must be awake) with a
             total of at least 7 successful readings over this period.

        Exclusion Criteria:

          -  Subject is taking â‰¥3 antihypertensive medications. (NOTE: A combination drug
             containing two antihypertensive agents represents two antihypertensive medications
             [e.g., Hyzaar is losartan potassium AND hydrochlorothiazide, therefore, counts as two
             antihypertensive medications].)

          -  Subject has DBP =90 mmHg (or for diabetic subjects, DBP =80 mmHg) on two
             antihypertensive medications.

          -  Subject has any known contraindication to ACE inhibitors (e.g., ACE-induced cough,
             angioedema or negative renal effects), or blocker treatment.

          -  Hyperkalemia or history of hyperkalemia resulting from either Type IV RTA (renal
             tubular acidosis) or previous ACEi therapy.

          -  Is female of childbearing potential. NOTE: Female subjects who are postmenopausal
             (i.e., no menstrual period for a minimum of 12 months prior to Screening) or
             surgically sterilized are eligible for the study. If judged appropriate, a
             postmenopausal woman may be required to have a documented negative urine pregnancy
             test.

          -  Subject has malignant (accelerated) hypertension, history of malignant hypertension,
             or secondary forms of hypertension.

          -  Subject has mean sitting SBP =180 mmHg.

          -  Subject has advanced hypertensive retinopathy (Keith Wagner Grade IV).

          -  Subject has Type 1 diabetes mellitus, or those with Type 2 having HbA1c â‰¥9% at
             Screening.

          -  Subject has uncorrected primary obstructive or severe regurgitative valvular disease,
             nondilated (restrictive) or hypertrophic cardiomyopathies.

          -  Subject has any of the following conditions:

        uncontrollable or symptomatic arrhythmias unstable angina or angina treated with a
        beta-blocker sick sinus syndrome or second or third degree heart block (unless treated with
        a permanent, functioning pacemaker) bradycardia (sitting heart rate &lt;55 bpm) history of
        myocardial infarction stroke within 3 months of Screening

          -  Subject is in atrial fibrillation.

          -  Subject has Congestive Heart Failure NYHA (New York Heart Association) class II-IV
             [The Criteria Committee of the New York Heart Association, 1994].

          -  Current clinical evidence of asthma or chronic obstructive pulmonary disease (e.g.,
             severe emphysema or chronic bronchitis) requiring long term use of inhaled oral
             bronchodilator or steroid drug therapy; also subjects with a history of bronchospastic
             disease not undergoing active therapy in whom, in the investigator's opinion,
             treatment with the study medication could provoke bronchospasm; or requirement for or
             anticipated treatment with beta-2 agonist therapy (e.g., albuterol [Ventolin,
             Proventil], metaproterenol [Alupent], pirbuterol [Maxair], terbutaline [Brethaire],
             isoetharine [Bronkosol], and Levalbuterol [Xopenex]).

          -  Subject has evidence of any of the following clinically significant diseases that
             could impair the absorption, metabolism, or excretion of orally-administered
             medication:

        renal disease defined as estimated Glomerular Filtration Rate (eGFR) &lt;30mL/min per 1.73 m2
        hepatic disease (i.e., ALT or AST levels greater than three times the upper limit of normal
        range, history of hepatic impairment, or by clinical assessment) chronic biliary disorders
        gastric bypass surgery

          -  Subject has endocrine disorders that affect blood pressure (e.g., pheochromocytoma,
             active and untreated hypo- or hyperthyroidism).

          -  Subject has systemic disease, including cancer, with reduced (&lt;12 months) life
             expectancy.

          -  Subject has used an investigational drug within 30 days or 5 half-lives (whichever is
             longer) preceding Screening.

          -  Subject has a history of a psychological illness/condition that would interfere with
             their ability to understand or complete the requirements of the study.

          -  Subject has any condition that, in the opinion of the Investigator and/or the GSK
             Medical Monitor, places the subject at an unacceptable risk as a participant in this
             trial.

          -  Subject is receiving ongoing treatment or is anticipated to receive treatment with any
             of the following medications during treatment with double blind study medication:

        any antihypertensive medication except for assigned study medication. This would include
        alpha blockers or other medications that may be used to treat hypertension and other
        conditions unrelated to hypertension; monoamine oxidase (MAO) inhibitors; any Class I or
        III antiarrhythmic; beta-2-agonists.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Haleyville</city>
        <state>Alabama</state>
        <zip>35565</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muscle Shoals</city>
        <state>Alabama</state>
        <zip>35662</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85296</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix, Arizona</city>
        <state>Arizona</state>
        <zip>86106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Searcy</city>
        <state>Arkansas</state>
        <zip>72143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beuna Park</city>
        <state>California</state>
        <zip>90620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Carlsbad</city>
        <state>California</state>
        <zip>92008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pico Rivera</city>
        <state>California</state>
        <zip>90660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rancho Cordova</city>
        <state>California</state>
        <zip>95670</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jacksonville Beach</city>
        <state>Florida</state>
        <zip>32250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33156</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sandersville</city>
        <state>Georgia</state>
        <zip>31082</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Illinois</state>
        <zip>60504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Melrose Park</city>
        <state>Illinois</state>
        <zip>60160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Avon</city>
        <state>Indiana</state>
        <zip>46123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bloomington</city>
        <state>Indiana</state>
        <zip>47102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Slidell</city>
        <state>Louisiana</state>
        <zip>70458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taunton</city>
        <state>Massachusetts</state>
        <zip>02780.</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bingham Farms</city>
        <state>Michigan</state>
        <zip>48025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brooklyn Center</city>
        <state>Minnesota</state>
        <zip>55430</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>O Fallon</city>
        <state>Montana</state>
        <zip>63366</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>08034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>7450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kingston</city>
        <state>New York</state>
        <zip>12401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lewinston</city>
        <state>New York</state>
        <zip>14092</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tonawanda</city>
        <state>New York</state>
        <zip>14150-1810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beaver</city>
        <state>Pennsylvania</state>
        <zip>15009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Doylestown</city>
        <state>Pennsylvania</state>
        <zip>18901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Havertown</city>
        <state>Pennsylvania</state>
        <zip>19083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Landsdale</city>
        <state>Pennsylvania</state>
        <zip>19446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leetsdale</city>
        <state>Pennsylvania</state>
        <zip>15056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19152</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Warminster</city>
        <state>Pennsylvania</state>
        <zip>18974</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Chester</city>
        <state>Pennsylvania</state>
        <zip>19380</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beaufort</city>
        <state>South Carolina</state>
        <zip>29906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gaffney</city>
        <state>South Carolina</state>
        <zip>29340</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hilton Head Island</city>
        <state>South Carolina</state>
        <zip>29926</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manning</city>
        <state>South Carolina</state>
        <zip>29102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Simpsonville</city>
        <state>South Carolina</state>
        <zip>29681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sumter</city>
        <state>South Carolina</state>
        <zip>29150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taylors</city>
        <state>South Carolina</state>
        <zip>29687</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Union</city>
        <state>South Carolina</state>
        <zip>29309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Clarksville</city>
        <state>Tennessee</state>
        <zip>37043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <zip>37601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Selmer</city>
        <state>Tennessee</state>
        <zip>38375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Georgetown</city>
        <state>Texas</state>
        <zip>78626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Grand Prairie/Texas</city>
        <state>Texas</state>
        <zip>5052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sandy</city>
        <state>Utah</state>
        <zip>84094</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Burke</city>
        <state>Virginia</state>
        <zip>22015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chester</city>
        <state>Virginia</state>
        <zip>23836</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manassas</city>
        <state>Virginia</state>
        <zip>20110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2006</study_first_submitted>
  <study_first_submitted_qc>June 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2006</study_first_posted>
  <results_first_submitted>April 22, 2009</results_first_submitted>
  <results_first_submitted_qc>September 28, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 9, 2009</results_first_posted>
  <last_update_submitted>November 3, 2016</last_update_submitted>
  <last_update_submitted_qc>November 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>carvedilol</keyword>
  <keyword>hypertension</keyword>
  <keyword>lisinopril</keyword>
  <keyword>factorial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
    <mesh_term>Lisinopril</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>CFD105453</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>CFD105453</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>CFD105453</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>CFD105453</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>CFD105453</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>CFD105453</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>CFD105453</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lisinopril 10</title>
          <description>lisinopril 10 milligrams (mg) once daily</description>
        </group>
        <group group_id="P2">
          <title>Lisinopril 20</title>
          <description>lisinopril 20 mg once daily</description>
        </group>
        <group group_id="P3">
          <title>Lisinopril 40</title>
          <description>lisinopril 40 mg once daily</description>
        </group>
        <group group_id="P4">
          <title>Carvedilol Controlled Release 20</title>
          <description>carvedilol controlled release (CR) 20 mg once daily</description>
        </group>
        <group group_id="P5">
          <title>Carvedilol Controlled Release 40</title>
          <description>carvedilol CR 40 mg once daily</description>
        </group>
        <group group_id="P6">
          <title>Carvedilol Controlled Release 80</title>
          <description>carvedilol CR 80 mg once daily</description>
        </group>
        <group group_id="P7">
          <title>Carvedilol Controlled Release 20 Lisinopril 10</title>
          <description>carvedilol CR 20 mg plus lisinopril 10 mg once daily</description>
        </group>
        <group group_id="P8">
          <title>Carvedilol Controlled Release 20 Lisinopril 20</title>
          <description>carvedilol CR 20 mg plus lisinopril 20 mg once daily</description>
        </group>
        <group group_id="P9">
          <title>Carvedilol Controlled Release 20 Lisinopril 40</title>
          <description>carvedilol CR 20 mg plus lisinopril 40 mg once daily</description>
        </group>
        <group group_id="P10">
          <title>Carvedilol Controlled Release 40 Lisinopril 10</title>
          <description>carvedilol CR 40 mg plus lisinopril 10 mg once daily</description>
        </group>
        <group group_id="P11">
          <title>Carvedilol Controlled Release 40 Lisinopril 20</title>
          <description>carvedilol CR 40 mg plus lisinopril 20 mg once daily</description>
        </group>
        <group group_id="P12">
          <title>Carvedilol Controlled Release 40 Lisinopril 40</title>
          <description>carvedilol CR 40 mg plus lisinopril 40 mg once daily</description>
        </group>
        <group group_id="P13">
          <title>Carvedilol Controlled Release 80 Lisinopril 10</title>
          <description>carvedilol CR 80 mg plus lisinopril 10 mg once daily</description>
        </group>
        <group group_id="P14">
          <title>Carvedilol Controlled Release 80 Lisinopril 20</title>
          <description>carvedilol CR 80 mg plus lisinopril 20 mg once daily</description>
        </group>
        <group group_id="P15">
          <title>Carvedilol Controlled Release 80 Lisinopril 40</title>
          <description>carvedilol CR 80 mg plus lisinopril 40 mg once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="43"/>
                <participants group_id="P4" count="43"/>
                <participants group_id="P5" count="44"/>
                <participants group_id="P6" count="44"/>
                <participants group_id="P7" count="44"/>
                <participants group_id="P8" count="43"/>
                <participants group_id="P9" count="44"/>
                <participants group_id="P10" count="44"/>
                <participants group_id="P11" count="44"/>
                <participants group_id="P12" count="43"/>
                <participants group_id="P13" count="44"/>
                <participants group_id="P14" count="44"/>
                <participants group_id="P15" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="30"/>
                <participants group_id="P5" count="39"/>
                <participants group_id="P6" count="36"/>
                <participants group_id="P7" count="37"/>
                <participants group_id="P8" count="40"/>
                <participants group_id="P9" count="38"/>
                <participants group_id="P10" count="35"/>
                <participants group_id="P11" count="39"/>
                <participants group_id="P12" count="37"/>
                <participants group_id="P13" count="34"/>
                <participants group_id="P14" count="36"/>
                <participants group_id="P15" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="9"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="6"/>
                <participants group_id="P13" count="10"/>
                <participants group_id="P14" count="8"/>
                <participants group_id="P15" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="3"/>
                <participants group_id="P11" count="3"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="3"/>
                <participants group_id="P14" count="2"/>
                <participants group_id="P15" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="3"/>
                <participants group_id="P13" count="4"/>
                <participants group_id="P14" count="2"/>
                <participants group_id="P15" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not listed/blank</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Per sponsors instruction</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>P.I. recommended due to blood pressure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject did not meet end of study ABPM</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal lab values</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>PI recommended early withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet criteria before ABPM</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized in error</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed inclusion criteria #4</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Prolonged duration between visits</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject left town, ran out of study drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject refuse to sign updated consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Visits conflicted with new job</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lisinopril 10</title>
          <description>lisinopril 10 milligrams (mg) once daily</description>
        </group>
        <group group_id="B2">
          <title>Lisinopril 20</title>
          <description>lisinopril 20 mg once daily</description>
        </group>
        <group group_id="B3">
          <title>Lisinopril 40</title>
          <description>lisinopril 40 mg once daily</description>
        </group>
        <group group_id="B4">
          <title>Carvedilol Controlled Release 20</title>
          <description>carvedilol controlled release (CR) 20 mg once daily</description>
        </group>
        <group group_id="B5">
          <title>Carvedilol Controlled Release 40</title>
          <description>carvedilol CR 40 mg once daily</description>
        </group>
        <group group_id="B6">
          <title>Carvedilol Controlled Release 80</title>
          <description>carvedilol CR 80 mg once daily</description>
        </group>
        <group group_id="B7">
          <title>Carvedilol Controlled Release 20 Lisinopril 10</title>
          <description>carvedilol CR 20 mg plus lisinopril 10 mg once daily</description>
        </group>
        <group group_id="B8">
          <title>Carvedilol Controlled Release 20 Lisinopril 20</title>
          <description>carvedilol CR 20 mg plus lisinopril 20 mg once daily</description>
        </group>
        <group group_id="B9">
          <title>Carvedilol Controlled Release 20 Lisinopril 40</title>
          <description>carvedilol CR 20 mg plus lisinopril 40 mg once daily</description>
        </group>
        <group group_id="B10">
          <title>Carvedilol Controlled Release 40 Lisinopril 10</title>
          <description>carvedilol CR 40 mg plus lisinopril 10 mg once daily</description>
        </group>
        <group group_id="B11">
          <title>Carvedilol Controlled Release 40 Lisinopril 20</title>
          <description>carvedilol CR 40 mg plus lisinopril 20 mg once daily</description>
        </group>
        <group group_id="B12">
          <title>Carvedilol Controlled Release 40 Lisinopril 40</title>
          <description>carvedilol CR 40 mg plus lisinopril 40 mg once daily</description>
        </group>
        <group group_id="B13">
          <title>Carvedilol Controlled Release 80 Lisinopril 10</title>
          <description>carvedilol CR 80 mg plus lisinopril 10 mg once daily</description>
        </group>
        <group group_id="B14">
          <title>Carvedilol Controlled Release 80 Lisinopril 20</title>
          <description>carvedilol CR 80 mg plus lisinopril 20 mg once daily</description>
        </group>
        <group group_id="B15">
          <title>Carvedilol Controlled Release 80 Lisinopril 40</title>
          <description>carvedilol CR 80 mg plus lisinopril 40 mg once daily</description>
        </group>
        <group group_id="B16">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="43"/>
            <count group_id="B4" value="43"/>
            <count group_id="B5" value="44"/>
            <count group_id="B6" value="44"/>
            <count group_id="B7" value="44"/>
            <count group_id="B8" value="43"/>
            <count group_id="B9" value="44"/>
            <count group_id="B10" value="44"/>
            <count group_id="B11" value="44"/>
            <count group_id="B12" value="43"/>
            <count group_id="B13" value="44"/>
            <count group_id="B14" value="44"/>
            <count group_id="B15" value="43"/>
            <count group_id="B16" value="654"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.3" spread="10.53"/>
                    <measurement group_id="B2" value="53.3" spread="10.69"/>
                    <measurement group_id="B3" value="51.1" spread="10.70"/>
                    <measurement group_id="B4" value="53.2" spread="9.41"/>
                    <measurement group_id="B5" value="54.1" spread="10.94"/>
                    <measurement group_id="B6" value="54.3" spread="8.64"/>
                    <measurement group_id="B7" value="53.3" spread="9.60"/>
                    <measurement group_id="B8" value="55.5" spread="8.39"/>
                    <measurement group_id="B9" value="53.5" spread="10.51"/>
                    <measurement group_id="B10" value="51.9" spread="9.08"/>
                    <measurement group_id="B11" value="51.5" spread="9.32"/>
                    <measurement group_id="B12" value="57.9" spread="9.27"/>
                    <measurement group_id="B13" value="52.5" spread="11.11"/>
                    <measurement group_id="B14" value="50.9" spread="9.51"/>
                    <measurement group_id="B15" value="51.5" spread="8.69"/>
                    <measurement group_id="B16" value="53.1" spread="9.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="13"/>
                    <measurement group_id="B8" value="18"/>
                    <measurement group_id="B9" value="14"/>
                    <measurement group_id="B10" value="13"/>
                    <measurement group_id="B11" value="13"/>
                    <measurement group_id="B12" value="18"/>
                    <measurement group_id="B13" value="15"/>
                    <measurement group_id="B14" value="14"/>
                    <measurement group_id="B15" value="14"/>
                    <measurement group_id="B16" value="232"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="32"/>
                    <measurement group_id="B6" value="25"/>
                    <measurement group_id="B7" value="31"/>
                    <measurement group_id="B8" value="25"/>
                    <measurement group_id="B9" value="30"/>
                    <measurement group_id="B10" value="31"/>
                    <measurement group_id="B11" value="31"/>
                    <measurement group_id="B12" value="25"/>
                    <measurement group_id="B13" value="29"/>
                    <measurement group_id="B14" value="30"/>
                    <measurement group_id="B15" value="29"/>
                    <measurement group_id="B16" value="422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African American/African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="13"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="11"/>
                    <measurement group_id="B9" value="12"/>
                    <measurement group_id="B10" value="18"/>
                    <measurement group_id="B11" value="14"/>
                    <measurement group_id="B12" value="13"/>
                    <measurement group_id="B13" value="16"/>
                    <measurement group_id="B14" value="14"/>
                    <measurement group_id="B15" value="11"/>
                    <measurement group_id="B16" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="3"/>
                    <measurement group_id="B14" value="3"/>
                    <measurement group_id="B15" value="4"/>
                    <measurement group_id="B16" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="29"/>
                    <measurement group_id="B7" value="30"/>
                    <measurement group_id="B8" value="30"/>
                    <measurement group_id="B9" value="29"/>
                    <measurement group_id="B10" value="23"/>
                    <measurement group_id="B11" value="27"/>
                    <measurement group_id="B12" value="27"/>
                    <measurement group_id="B13" value="25"/>
                    <measurement group_id="B14" value="26"/>
                    <measurement group_id="B15" value="27"/>
                    <measurement group_id="B16" value="417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Race not provided by patient</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 6 in 24 Hour (hr) Mean Diastolic Blood Pressure</title>
        <description>Ambulatory blood pressure monitoring (ABPM) was completed at Baseline and at the end of treatment/Week 6 or early withdrawal by standard electronic ABPM equipment worn by the subject for 24-hr of ambulatory activity. The 24 hr assessment period started at the time of the first reading and ended exactly 24 hr later on the following day. Data collected included mean diastolic blood pressure (DBP).</description>
        <time_frame>Baseline, Week 6.</time_frame>
        <population>ABPM Population with Last Observation Carried Forward (LOCF): This comprised all randomized subjects with efficacy (vital signs) data after a minimum of 2 weeks on treatment with valid Baseline and on-therapy ABPM measures. All efficacy data derived from ABPM assessments were summarized by this population.</population>
        <group_list>
          <group group_id="O1">
            <title>Lisinopril 10</title>
            <description>lisinopril 10 milligrams (mg) once daily</description>
          </group>
          <group group_id="O2">
            <title>Lisinopril 20</title>
            <description>lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Lisinopril 40</title>
            <description>lisinopril 40 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Carvedilol Controlled Release 20</title>
            <description>carvedilol controlled release (CR) 20 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Carvedilol Controlled Release 40</title>
            <description>carvedilol CR 40 mg once daily</description>
          </group>
          <group group_id="O6">
            <title>Carvedilol Controlled Release 80</title>
            <description>carvedilol CR 80 mg once daily</description>
          </group>
          <group group_id="O7">
            <title>Carvedilol Controlled Release 20 Lisinopril 10</title>
            <description>carvedilol CR 20 mg plus lisinopril 10 mg once daily</description>
          </group>
          <group group_id="O8">
            <title>Carvedilol Controlled Release 20 Lisinopril 20</title>
            <description>carvedilol CR 20 mg plus lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O9">
            <title>Carvedilol Controlled Release 20 Lisinopril 40</title>
            <description>carvedilol CR 20 mg plus lisinopril 40 mg once daily</description>
          </group>
          <group group_id="O10">
            <title>Carvedilol Controlled Release 40 Lisinopril 10</title>
            <description>carvedilol CR 40 mg plus lisinopril 10 mg once daily</description>
          </group>
          <group group_id="O11">
            <title>Carvedilol Controlled Release 40 Lisinopril 20</title>
            <description>carvedilol CR 40 mg plus lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O12">
            <title>Carvedilol Controlled Release 40 Lisinopril 40</title>
            <description>carvedilol CR 40 mg plus lisinopril 40 mg once daily</description>
          </group>
          <group group_id="O13">
            <title>Carvedilol Controlled Release 80 Lisinopril 10</title>
            <description>carvedilol CR 80 mg plus lisinopril 10 mg once daily</description>
          </group>
          <group group_id="O14">
            <title>Carvedilol Controlled Release 80 Lisinopril 20</title>
            <description>carvedilol CR 80 mg plus lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O15">
            <title>Carvedilol Controlled Release 80 Lisinopril 40</title>
            <description>carvedilol CR 80 mg plus lisinopril 40 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 6 in 24 Hour (hr) Mean Diastolic Blood Pressure</title>
          <description>Ambulatory blood pressure monitoring (ABPM) was completed at Baseline and at the end of treatment/Week 6 or early withdrawal by standard electronic ABPM equipment worn by the subject for 24-hr of ambulatory activity. The 24 hr assessment period started at the time of the first reading and ended exactly 24 hr later on the following day. Data collected included mean diastolic blood pressure (DBP).</description>
          <population>ABPM Population with Last Observation Carried Forward (LOCF): This comprised all randomized subjects with efficacy (vital signs) data after a minimum of 2 weeks on treatment with valid Baseline and on-therapy ABPM measures. All efficacy data derived from ABPM assessments were summarized by this population.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="35"/>
                <count group_id="O8" value="37"/>
                <count group_id="O9" value="34"/>
                <count group_id="O10" value="32"/>
                <count group_id="O11" value="35"/>
                <count group_id="O12" value="34"/>
                <count group_id="O13" value="28"/>
                <count group_id="O14" value="33"/>
                <count group_id="O15" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.79" spread="5.922"/>
                    <measurement group_id="O2" value="-8.11" spread="8.811"/>
                    <measurement group_id="O3" value="-7.37" spread="5.914"/>
                    <measurement group_id="O4" value="-4.40" spread="5.182"/>
                    <measurement group_id="O5" value="-7.61" spread="4.880"/>
                    <measurement group_id="O6" value="-6.52" spread="6.408"/>
                    <measurement group_id="O7" value="-9.29" spread="7.226"/>
                    <measurement group_id="O8" value="-8.57" spread="6.585"/>
                    <measurement group_id="O9" value="-10.19" spread="6.899"/>
                    <measurement group_id="O10" value="-9.36" spread="7.426"/>
                    <measurement group_id="O11" value="-10.96" spread="8.388"/>
                    <measurement group_id="O12" value="-10.37" spread="7.234"/>
                    <measurement group_id="O13" value="-10.93" spread="5.517"/>
                    <measurement group_id="O14" value="-11.09" spread="8.719"/>
                    <measurement group_id="O15" value="-11.92" spread="6.887"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
              <group_id>O11</group_id>
              <group_id>O12</group_id>
              <group_id>O13</group_id>
              <group_id>O14</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <groups_desc>This is an omnibus test to investigate the existence of at least one combination dose that outperforms its components.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.1</p_value>
            <method>Hung AVE test, see comments</method>
            <method_desc>Hung AVE Test Statistic: -0.41499. Tests an average of the minimum gains (in response) for the 9 combination cells over corresponding monotherapies.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 6 in Trough Diastolic Blood Pressure</title>
        <description>Trough ABPM was the average across 20-24 hr after dosing for each subject.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>ABPM Population with LOCF: This comprised all randomized subjects with efficacy (vital signs) data after a minimum of 2 weeks on treatment with valid Baseline and on-therapy ABPM measures. All efficacy data derived from ABPM assessments were summarized by this population</population>
        <group_list>
          <group group_id="O1">
            <title>Lisinopril 10</title>
            <description>lisinopril 10 milligrams (mg) once daily</description>
          </group>
          <group group_id="O2">
            <title>Lisinopril 20</title>
            <description>lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Lisinopril 40</title>
            <description>lisinopril 40 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Carvedilol Controlled Release 20</title>
            <description>carvedilol controlled release (CR) 20 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Carvedilol Controlled Release 40</title>
            <description>carvedilol CR 40 mg once daily</description>
          </group>
          <group group_id="O6">
            <title>Carvedilol Controlled Release 80</title>
            <description>carvedilol CR 80 mg once daily</description>
          </group>
          <group group_id="O7">
            <title>Carvedilol Controlled Release 20 Lisinopril 10</title>
            <description>carvedilol CR 20 mg plus lisinopril 10 mg once daily</description>
          </group>
          <group group_id="O8">
            <title>Carvedilol Controlled Release 20 Lisinopril 20</title>
            <description>carvedilol CR 20 mg plus lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O9">
            <title>Carvedilol Controlled Release 20 Lisinopril 40</title>
            <description>carvedilol CR 20 mg plus lisinopril 40 mg once daily</description>
          </group>
          <group group_id="O10">
            <title>Carvedilol Controlled Release 40 Lisinopril 10</title>
            <description>carvedilol CR 40 mg plus lisinopril 10 mg once daily</description>
          </group>
          <group group_id="O11">
            <title>Carvedilol Controlled Release 40 Lisinopril 20</title>
            <description>carvedilol CR 40 mg plus lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O12">
            <title>Carvedilol Controlled Release 40 Lisinopril 40</title>
            <description>carvedilol CR 40 mg plus lisinopril 40 mg once daily</description>
          </group>
          <group group_id="O13">
            <title>Carvedilol Controlled Release 80 Lisinopril 10</title>
            <description>carvedilol CR 80 mg plus lisinopril 10 mg once daily</description>
          </group>
          <group group_id="O14">
            <title>Carvedilol Controlled Release 80 Lisinopril 20</title>
            <description>carvedilol CR 80 mg plus lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O15">
            <title>Carvedilol Controlled Release 80 Lisinopril 40</title>
            <description>carvedilol CR 80 mg plus lisinopril 40 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 6 in Trough Diastolic Blood Pressure</title>
          <description>Trough ABPM was the average across 20-24 hr after dosing for each subject.</description>
          <population>ABPM Population with LOCF: This comprised all randomized subjects with efficacy (vital signs) data after a minimum of 2 weeks on treatment with valid Baseline and on-therapy ABPM measures. All efficacy data derived from ABPM assessments were summarized by this population</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="33"/>
                <count group_id="O8" value="35"/>
                <count group_id="O9" value="34"/>
                <count group_id="O10" value="29"/>
                <count group_id="O11" value="33"/>
                <count group_id="O12" value="33"/>
                <count group_id="O13" value="28"/>
                <count group_id="O14" value="33"/>
                <count group_id="O15" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.40" spread="7.982"/>
                    <measurement group_id="O2" value="-6.08" spread="8.735"/>
                    <measurement group_id="O3" value="-8.16" spread="7.299"/>
                    <measurement group_id="O4" value="-2.34" spread="7.060"/>
                    <measurement group_id="O5" value="-7.76" spread="8.285"/>
                    <measurement group_id="O6" value="-5.26" spread="9.530"/>
                    <measurement group_id="O7" value="-5.14" spread="7.002"/>
                    <measurement group_id="O8" value="-6.36" spread="9.080"/>
                    <measurement group_id="O9" value="-7.22" spread="11.284"/>
                    <measurement group_id="O10" value="-6.79" spread="9.210"/>
                    <measurement group_id="O11" value="-7.76" spread="11.202"/>
                    <measurement group_id="O12" value="-4.90" spread="8.508"/>
                    <measurement group_id="O13" value="-6.54" spread="8.305"/>
                    <measurement group_id="O14" value="-7.26" spread="9.345"/>
                    <measurement group_id="O15" value="-8.42" spread="7.903"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
              <group_id>O11</group_id>
              <group_id>O12</group_id>
              <group_id>O13</group_id>
              <group_id>O14</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <groups_desc>This is an omnibus test to investigate the existence of at least one combination dose that outperforms its components.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.1</p_value>
            <method>Hung AVE test, see comments</method>
            <method_desc>Hung AVE Test Statistic: -0.00485. Tests an average of the minimum gains (in response) for the 9 combination cells over corresponding monotherapies.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 6 in 24 Hour Mean Systolic Blood Pressure</title>
        <description>Ambulatory blood pressure monitoring (ABPM) was completed at Baseline and at the end of treatment/Week 6 or early withdrawal by standard electronic ABPM equipment worn by the subject for 24-hr of ambulatory activity. The 24 hr assessment period started at the time of the first reading and ended exactly 24 hr later on the following day. Data collected included mean systolic blood pressure (SBP).</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>ABPM Population with LOCF: This comprised all randomized subjects with efficacy (vital signs) data after a minimum of 2 weeks on treatment with valid Baseline and on-therapy ABPM measures. All efficacy data derived from ABPM assessments were summarized by this population</population>
        <group_list>
          <group group_id="O1">
            <title>Lisinopril 10</title>
            <description>lisinopril 10 milligrams (mg) once daily</description>
          </group>
          <group group_id="O2">
            <title>Lisinopril 20</title>
            <description>lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Lisinopril 40</title>
            <description>lisinopril 40 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Carvedilol Controlled Release 20</title>
            <description>carvedilol controlled release (CR) 20 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Carvedilol Controlled Release 40</title>
            <description>carvedilol CR 40 mg once daily</description>
          </group>
          <group group_id="O6">
            <title>Carvedilol Controlled Release 80</title>
            <description>carvedilol CR 80 mg once daily</description>
          </group>
          <group group_id="O7">
            <title>Carvedilol Controlled Release 20 Lisinopril 10</title>
            <description>carvedilol CR 20 mg plus lisinopril 10 mg once daily</description>
          </group>
          <group group_id="O8">
            <title>Carvedilol Controlled Release 20 Lisinopril 20</title>
            <description>carvedilol CR 20 mg plus lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O9">
            <title>Carvedilol Controlled Release 20 Lisinopril 40</title>
            <description>carvedilol CR 20 mg plus lisinopril 40 mg once daily</description>
          </group>
          <group group_id="O10">
            <title>Carvedilol Controlled Release 40 Lisinopril 10</title>
            <description>carvedilol CR 40 mg plus lisinopril 10 mg once daily</description>
          </group>
          <group group_id="O11">
            <title>Carvedilol Controlled Release 40 Lisinopril 20</title>
            <description>carvedilol CR 40 mg plus lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O12">
            <title>Carvedilol Controlled Release 40 Lisinopril 40</title>
            <description>carvedilol CR 40 mg plus lisinopril 40 mg once daily</description>
          </group>
          <group group_id="O13">
            <title>Carvedilol Controlled Release 80 Lisinopril 10</title>
            <description>carvedilol CR 80 mg plus lisinopril 10 mg once daily</description>
          </group>
          <group group_id="O14">
            <title>Carvedilol Controlled Release 80 Lisinopril 20</title>
            <description>carvedilol CR 80 mg plus lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O15">
            <title>Carvedilol Controlled Release 80 Lisinopril 40</title>
            <description>carvedilol CR 80 mg plus lisinopril 40 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 6 in 24 Hour Mean Systolic Blood Pressure</title>
          <description>Ambulatory blood pressure monitoring (ABPM) was completed at Baseline and at the end of treatment/Week 6 or early withdrawal by standard electronic ABPM equipment worn by the subject for 24-hr of ambulatory activity. The 24 hr assessment period started at the time of the first reading and ended exactly 24 hr later on the following day. Data collected included mean systolic blood pressure (SBP).</description>
          <population>ABPM Population with LOCF: This comprised all randomized subjects with efficacy (vital signs) data after a minimum of 2 weeks on treatment with valid Baseline and on-therapy ABPM measures. All efficacy data derived from ABPM assessments were summarized by this population</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="35"/>
                <count group_id="O8" value="37"/>
                <count group_id="O9" value="34"/>
                <count group_id="O10" value="32"/>
                <count group_id="O11" value="35"/>
                <count group_id="O12" value="34"/>
                <count group_id="O13" value="28"/>
                <count group_id="O14" value="33"/>
                <count group_id="O15" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.19" spread="9.415"/>
                    <measurement group_id="O2" value="-13.58" spread="16.429"/>
                    <measurement group_id="O3" value="-10.60" spread="8.842"/>
                    <measurement group_id="O4" value="-6.15" spread="6.887"/>
                    <measurement group_id="O5" value="-9.84" spread="8.471"/>
                    <measurement group_id="O6" value="-10.38" spread="8.204"/>
                    <measurement group_id="O7" value="-12.06" spread="11.058"/>
                    <measurement group_id="O8" value="-11.58" spread="11.112"/>
                    <measurement group_id="O9" value="-14.16" spread="10.783"/>
                    <measurement group_id="O10" value="-11.68" spread="10.218"/>
                    <measurement group_id="O11" value="-14.03" spread="11.954"/>
                    <measurement group_id="O12" value="-13.90" spread="10.237"/>
                    <measurement group_id="O13" value="-15.60" spread="9.777"/>
                    <measurement group_id="O14" value="-15.93" spread="12.501"/>
                    <measurement group_id="O15" value="-15.59" spread="11.055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 6 in Trough Systolic Blood Pressure</title>
        <description>Trough ABPM was the average across 20-24 hr after dosing for each subject.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>ABPM Population with LOCF: This comprised all randomized subjects with efficacy (vital signs) data after a minimum of 2 weeks on treatment with valid Baseline and on-therapy ABPM measures. All efficacy data derived from ABPM assessments were summarized by this population</population>
        <group_list>
          <group group_id="O1">
            <title>Lisinopril 10</title>
            <description>lisinopril 10 milligrams (mg) once daily</description>
          </group>
          <group group_id="O2">
            <title>Lisinopril 20</title>
            <description>lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Lisinopril 40</title>
            <description>lisinopril 40 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Carvedilol Controlled Release 20</title>
            <description>carvedilol controlled release (CR) 20 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Carvedilol Controlled Release 40</title>
            <description>carvedilol CR 40 mg once daily</description>
          </group>
          <group group_id="O6">
            <title>Carvedilol Controlled Release 80</title>
            <description>carvedilol CR 80 mg once daily</description>
          </group>
          <group group_id="O7">
            <title>Carvedilol Controlled Release 20 Lisinopril 10</title>
            <description>carvedilol CR 20 mg plus lisinopril 10 mg once daily</description>
          </group>
          <group group_id="O8">
            <title>Carvedilol Controlled Release 20 Lisinopril 20</title>
            <description>carvedilol CR 20 mg plus lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O9">
            <title>Carvedilol Controlled Release 20 Lisinopril 40</title>
            <description>carvedilol CR 20 mg plus lisinopril 40 mg once daily</description>
          </group>
          <group group_id="O10">
            <title>Carvedilol Controlled Release 40 Lisinopril 10</title>
            <description>carvedilol CR 40 mg plus lisinopril 10 mg once daily</description>
          </group>
          <group group_id="O11">
            <title>Carvedilol Controlled Release 40 Lisinopril 20</title>
            <description>carvedilol CR 40 mg plus lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O12">
            <title>Carvedilol Controlled Release 40 Lisinopril 40</title>
            <description>carvedilol CR 40 mg plus lisinopril 40 mg once daily</description>
          </group>
          <group group_id="O13">
            <title>Carvedilol Controlled Release 80 Lisinopril 10</title>
            <description>carvedilol CR 80 mg plus lisinopril 10 mg once daily</description>
          </group>
          <group group_id="O14">
            <title>Carvedilol Controlled Release 80 Lisinopril 20</title>
            <description>carvedilol CR 80 mg plus lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O15">
            <title>Carvedilol Controlled Release 80 Lisinopril 40</title>
            <description>carvedilol CR 80 mg plus lisinopril 40 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 6 in Trough Systolic Blood Pressure</title>
          <description>Trough ABPM was the average across 20-24 hr after dosing for each subject.</description>
          <population>ABPM Population with LOCF: This comprised all randomized subjects with efficacy (vital signs) data after a minimum of 2 weeks on treatment with valid Baseline and on-therapy ABPM measures. All efficacy data derived from ABPM assessments were summarized by this population</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="33"/>
                <count group_id="O8" value="35"/>
                <count group_id="O9" value="34"/>
                <count group_id="O10" value="29"/>
                <count group_id="O11" value="33"/>
                <count group_id="O12" value="33"/>
                <count group_id="O13" value="28"/>
                <count group_id="O14" value="33"/>
                <count group_id="O15" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.47" spread="13.301"/>
                    <measurement group_id="O2" value="-7.52" spread="12.221"/>
                    <measurement group_id="O3" value="-9.54" spread="9.968"/>
                    <measurement group_id="O4" value="-0.96" spread="11.447"/>
                    <measurement group_id="O5" value="-9.27" spread="12.362"/>
                    <measurement group_id="O6" value="-5.68" spread="14.539"/>
                    <measurement group_id="O7" value="-6.44" spread="9.739"/>
                    <measurement group_id="O8" value="-9.27" spread="13.582"/>
                    <measurement group_id="O9" value="-9.88" spread="14.356"/>
                    <measurement group_id="O10" value="-8.87" spread="11.954"/>
                    <measurement group_id="O11" value="-8.11" spread="13.732"/>
                    <measurement group_id="O12" value="-5.82" spread="13.878"/>
                    <measurement group_id="O13" value="-9.80" spread="11.196"/>
                    <measurement group_id="O14" value="-10.74" spread="12.813"/>
                    <measurement group_id="O15" value="-10.00" spread="12.091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose-response Treatment Estimates: Change From Baseline to Week 6 in 24 Hour Mean DBP by ABPM (Ambulatory Blood Pressure Monitoring)</title>
        <description>Evaluation of the dose-response relationship between incremental doses of carvedilol CR and lisinopril and mean 24-hr ABPM DBP.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>ABPM Population with LOCF: This comprised all randomized subjects with efficacy (vital signs) data after a minimum of 2 weeks on treatment with valid Baseline and on-therapy ABPM measures. All efficacy data derived from ABPM assessments were summarized by this population</population>
        <group_list>
          <group group_id="O1">
            <title>Lisinopril 10</title>
            <description>lisinopril 10 milligrams (mg) once daily</description>
          </group>
          <group group_id="O2">
            <title>Lisinopril 20</title>
            <description>lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Lisinopril 40</title>
            <description>lisinopril 40 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Carvedilol Controlled Release 20</title>
            <description>carvedilol controlled release (CR) 20 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Carvedilol Controlled Release 40</title>
            <description>carvedilol CR 40 mg once daily</description>
          </group>
          <group group_id="O6">
            <title>Carvedilol Controlled Release 80</title>
            <description>carvedilol CR 80 mg once daily</description>
          </group>
          <group group_id="O7">
            <title>Carvedilol Controlled Release 20 Lisinopril 10</title>
            <description>carvedilol CR 20 mg plus lisinopril 10 mg once daily</description>
          </group>
          <group group_id="O8">
            <title>Carvedilol Controlled Release 20 Lisinopril 20</title>
            <description>carvedilol CR 20 mg plus lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O9">
            <title>Carvedilol Controlled Release 20 Lisinopril 40</title>
            <description>carvedilol CR 20 mg plus lisinopril 40 mg once daily</description>
          </group>
          <group group_id="O10">
            <title>Carvedilol Controlled Release 40 Lisinopril 10</title>
            <description>carvedilol CR 40 mg plus lisinopril 10 mg once daily</description>
          </group>
          <group group_id="O11">
            <title>Carvedilol Controlled Release 40 Lisinopril 20</title>
            <description>carvedilol CR 40 mg plus lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O12">
            <title>Carvedilol Controlled Release 40 Lisinopril 40</title>
            <description>carvedilol CR 40 mg plus lisinopril 40 mg once daily</description>
          </group>
          <group group_id="O13">
            <title>Carvedilol Controlled Release 80 Lisinopril 10</title>
            <description>carvedilol CR 80 mg plus lisinopril 10 mg once daily</description>
          </group>
          <group group_id="O14">
            <title>Carvedilol Controlled Release 80 Lisinopril 20</title>
            <description>carvedilol CR 80 mg plus lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O15">
            <title>Carvedilol Controlled Release 80 Lisinopril 40</title>
            <description>carvedilol CR 80 mg plus lisinopril 40 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-response Treatment Estimates: Change From Baseline to Week 6 in 24 Hour Mean DBP by ABPM (Ambulatory Blood Pressure Monitoring)</title>
          <description>Evaluation of the dose-response relationship between incremental doses of carvedilol CR and lisinopril and mean 24-hr ABPM DBP.</description>
          <population>ABPM Population with LOCF: This comprised all randomized subjects with efficacy (vital signs) data after a minimum of 2 weeks on treatment with valid Baseline and on-therapy ABPM measures. All efficacy data derived from ABPM assessments were summarized by this population</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="35"/>
                <count group_id="O8" value="37"/>
                <count group_id="O9" value="34"/>
                <count group_id="O10" value="32"/>
                <count group_id="O11" value="35"/>
                <count group_id="O12" value="34"/>
                <count group_id="O13" value="28"/>
                <count group_id="O14" value="33"/>
                <count group_id="O15" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.77" spread="0.821"/>
                    <measurement group_id="O2" value="-7.55" spread="0.717"/>
                    <measurement group_id="O3" value="-7.49" spread="0.877"/>
                    <measurement group_id="O4" value="-5.11" spread="0.821"/>
                    <measurement group_id="O5" value="-6.61" spread="0.718"/>
                    <measurement group_id="O6" value="-7.13" spread="0.925"/>
                    <measurement group_id="O7" value="-8.08" spread="0.472"/>
                    <measurement group_id="O8" value="-9.83" spread="0.536"/>
                    <measurement group_id="O9" value="-9.71" spread="0.657"/>
                    <measurement group_id="O10" value="-9.55" spread="0.534"/>
                    <measurement group_id="O11" value="-11.3" spread="0.645"/>
                    <measurement group_id="O12" value="-11.1" spread="0.702"/>
                    <measurement group_id="O13" value="-10.0" spread="0.696"/>
                    <measurement group_id="O14" value="-11.7" spread="0.722"/>
                    <measurement group_id="O15" value="-11.4" spread="1.042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 6 in Trough to Peak Ratios of DBP by 24 Hour ABPM (Ambulatory Blood Pressure Monitoring)</title>
        <description>Trough (20-24 hr) to peak (3-7 hr) ratios of DBP were examined in order to evaluate the extent to which once-daily criteria were met (ie trough:peak &gt; 50%). Trough to peak ratios were calculated from change trough mean/change peak mean x 100.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>ABPM Population with LOCF: This comprised all randomized subjects with efficacy (vital signs) data after a minimum of 2 weeks on treatment with valid Baseline and on-therapy ABPM measures. All efficacy data derived from ABPM assessments were summarized by this population</population>
        <group_list>
          <group group_id="O1">
            <title>Lisinopril 10</title>
            <description>lisinopril 10 milligrams (mg) once daily</description>
          </group>
          <group group_id="O2">
            <title>Lisinopril 20</title>
            <description>lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Lisinopril 40</title>
            <description>lisinopril 40 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Carvedilol Controlled Release 20</title>
            <description>carvedilol controlled release (CR) 20 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Carvedilol Controlled Release 40</title>
            <description>carvedilol CR 40 mg once daily</description>
          </group>
          <group group_id="O6">
            <title>Carvedilol Controlled Release 80</title>
            <description>carvedilol CR 80 mg once daily</description>
          </group>
          <group group_id="O7">
            <title>Carvedilol Controlled Release 20 Lisinopril 10</title>
            <description>carvedilol CR 20 mg plus lisinopril 10 mg once daily</description>
          </group>
          <group group_id="O8">
            <title>Carvedilol Controlled Release 20 Lisinopril 20</title>
            <description>carvedilol CR 20 mg plus lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O9">
            <title>Carvedilol Controlled Release 20 Lisinopril 40</title>
            <description>carvedilol CR 20 mg plus lisinopril 40 mg once daily</description>
          </group>
          <group group_id="O10">
            <title>Carvedilol Controlled Release 40 Lisinopril 10</title>
            <description>carvedilol CR 40 mg plus lisinopril 10 mg once daily</description>
          </group>
          <group group_id="O11">
            <title>Carvedilol Controlled Release 40 Lisinopril 20</title>
            <description>carvedilol CR 40 mg plus lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O12">
            <title>Carvedilol Controlled Release 40 Lisinopril 40</title>
            <description>carvedilol CR 40 mg plus lisinopril 40 mg once daily</description>
          </group>
          <group group_id="O13">
            <title>Carvedilol Controlled Release 80 Lisinopril 10</title>
            <description>carvedilol CR 80 mg plus lisinopril 10 mg once daily</description>
          </group>
          <group group_id="O14">
            <title>Carvedilol Controlled Release 80 Lisinopril 20</title>
            <description>carvedilol CR 80 mg plus lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O15">
            <title>Carvedilol Controlled Release 80 Lisinopril 40</title>
            <description>carvedilol CR 80 mg plus lisinopril 40 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 6 in Trough to Peak Ratios of DBP by 24 Hour ABPM (Ambulatory Blood Pressure Monitoring)</title>
          <description>Trough (20-24 hr) to peak (3-7 hr) ratios of DBP were examined in order to evaluate the extent to which once-daily criteria were met (ie trough:peak &gt; 50%). Trough to peak ratios were calculated from change trough mean/change peak mean x 100.</description>
          <population>ABPM Population with LOCF: This comprised all randomized subjects with efficacy (vital signs) data after a minimum of 2 weeks on treatment with valid Baseline and on-therapy ABPM measures. All efficacy data derived from ABPM assessments were summarized by this population</population>
          <units>trough:peak ratio x 100%</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="33"/>
                <count group_id="O8" value="35"/>
                <count group_id="O9" value="34"/>
                <count group_id="O10" value="29"/>
                <count group_id="O11" value="33"/>
                <count group_id="O12" value="34"/>
                <count group_id="O13" value="28"/>
                <count group_id="O14" value="33"/>
                <count group_id="O15" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.33"/>
                    <measurement group_id="O2" value="61.04"/>
                    <measurement group_id="O3" value="114.45"/>
                    <measurement group_id="O4" value="34.11"/>
                    <measurement group_id="O5" value="71.00"/>
                    <measurement group_id="O6" value="49.67"/>
                    <measurement group_id="O7" value="44.50"/>
                    <measurement group_id="O8" value="49.46"/>
                    <measurement group_id="O9" value="59.47"/>
                    <measurement group_id="O10" value="54.71"/>
                    <measurement group_id="O11" value="52.86"/>
                    <measurement group_id="O12" value="37.93"/>
                    <measurement group_id="O13" value="41.95"/>
                    <measurement group_id="O14" value="53.54"/>
                    <measurement group_id="O15" value="52.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Description of Safety in Each Treatment Group Using Adverse Events, Laboratory Evaluations, ECG Changes, Vital Sign Changes, and Withdrawal Rates.</title>
        <description>Refer to Adverse Event section for safety information.</description>
        <time_frame>Weeks 1 through 48</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 6 in Mean SBP and DBP Measured in Morning by 24 Hour ABPM</title>
        <description>Mean changes from Baseline to Week 6 in DBP and SBP measured by 24hr ABPM at the end of up-titration recorded in the morning. The morning assessment period started at or after 6 am and ended immediately before 12 noon.</description>
        <time_frame>Morning BP, Baseline, Week 6</time_frame>
        <population>ABPM Population with LOCF: This comprised all randomized subjects with efficacy (vital signs) data after a minimum of 2 weeks on treatment with valid Baseline and on-therapy ABPM measures. All efficacy data derived from ABPM assessments were summarized by this population</population>
        <group_list>
          <group group_id="O1">
            <title>Lisinopril 10</title>
            <description>lisinopril 10 milligrams (mg) once daily</description>
          </group>
          <group group_id="O2">
            <title>Lisinopril 20</title>
            <description>lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Lisinopril 40</title>
            <description>lisinopril 40 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Carvedilol Controlled Release 20</title>
            <description>carvedilol controlled release (CR) 20 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Carvedilol Controlled Release 40</title>
            <description>carvedilol CR 40 mg once daily</description>
          </group>
          <group group_id="O6">
            <title>Carvedilol Controlled Release 80</title>
            <description>carvedilol CR 80 mg once daily</description>
          </group>
          <group group_id="O7">
            <title>Carvedilol Controlled Release 20 Lisinopril 10</title>
            <description>carvedilol CR 20 mg plus lisinopril 10 mg once daily</description>
          </group>
          <group group_id="O8">
            <title>Carvedilol Controlled Release 20 Lisinopril 20</title>
            <description>carvedilol CR 20 mg plus lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O9">
            <title>Carvedilol Controlled Release 20 Lisinopril 40</title>
            <description>carvedilol CR 20 mg plus lisinopril 40 mg once daily</description>
          </group>
          <group group_id="O10">
            <title>Carvedilol Controlled Release 40 Lisinopril 10</title>
            <description>carvedilol CR 40 mg plus lisinopril 10 mg once daily</description>
          </group>
          <group group_id="O11">
            <title>Carvedilol Controlled Release 40 Lisinopril 20</title>
            <description>carvedilol CR 40 mg plus lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O12">
            <title>Carvedilol Controlled Release 40 Lisinopril 40</title>
            <description>carvedilol CR 40 mg plus lisinopril 40 mg once daily</description>
          </group>
          <group group_id="O13">
            <title>Carvedilol Controlled Release 80 Lisinopril 10</title>
            <description>carvedilol CR 80 mg plus lisinopril 10 mg once daily</description>
          </group>
          <group group_id="O14">
            <title>Carvedilol Controlled Release 80 Lisinopril 20</title>
            <description>carvedilol CR 80 mg plus lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O15">
            <title>Carvedilol Controlled Release 80 Lisinopril 40</title>
            <description>carvedilol CR 80 mg plus lisinopril 40 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 6 in Mean SBP and DBP Measured in Morning by 24 Hour ABPM</title>
          <description>Mean changes from Baseline to Week 6 in DBP and SBP measured by 24hr ABPM at the end of up-titration recorded in the morning. The morning assessment period started at or after 6 am and ended immediately before 12 noon.</description>
          <population>ABPM Population with LOCF: This comprised all randomized subjects with efficacy (vital signs) data after a minimum of 2 weeks on treatment with valid Baseline and on-therapy ABPM measures. All efficacy data derived from ABPM assessments were summarized by this population</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="32"/>
                <count group_id="O7" value="35"/>
                <count group_id="O8" value="37"/>
                <count group_id="O9" value="34"/>
                <count group_id="O10" value="32"/>
                <count group_id="O11" value="35"/>
                <count group_id="O12" value="34"/>
                <count group_id="O13" value="28"/>
                <count group_id="O14" value="33"/>
                <count group_id="O15" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in Morning SBP from Baseline to Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.37" spread="9.564"/>
                    <measurement group_id="O2" value="-14.53" spread="17.166"/>
                    <measurement group_id="O3" value="-10.76" spread="9.112"/>
                    <measurement group_id="O4" value="-6.23" spread="9.159"/>
                    <measurement group_id="O5" value="-10.42" spread="8.815"/>
                    <measurement group_id="O6" value="-13.70" spread="10.056"/>
                    <measurement group_id="O7" value="-13.89" spread="12.288"/>
                    <measurement group_id="O8" value="-10.22" spread="12.734"/>
                    <measurement group_id="O9" value="-14.50" spread="12.031"/>
                    <measurement group_id="O10" value="-12.78" spread="14.700"/>
                    <measurement group_id="O11" value="-14.29" spread="14.136"/>
                    <measurement group_id="O12" value="-14.84" spread="13.383"/>
                    <measurement group_id="O13" value="-17.09" spread="13.194"/>
                    <measurement group_id="O14" value="-14.52" spread="15.111"/>
                    <measurement group_id="O15" value="-17.12" spread="14.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Morning DBP from Baseline to Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.12" spread="8.457"/>
                    <measurement group_id="O2" value="-9.20" spread="10.516"/>
                    <measurement group_id="O3" value="-7.62" spread="8.033"/>
                    <measurement group_id="O4" value="-5.01" spread="7.141"/>
                    <measurement group_id="O5" value="-6.82" spread="6.279"/>
                    <measurement group_id="O6" value="-7.53" spread="8.206"/>
                    <measurement group_id="O7" value="-9.21" spread="9.474"/>
                    <measurement group_id="O8" value="-7.86" spread="8.416"/>
                    <measurement group_id="O9" value="-10.04" spread="8.489"/>
                    <measurement group_id="O10" value="-8.79" spread="10.902"/>
                    <measurement group_id="O11" value="-11.15" spread="10.411"/>
                    <measurement group_id="O12" value="-9.96" spread="10.730"/>
                    <measurement group_id="O13" value="-11.95" spread="8.060"/>
                    <measurement group_id="O14" value="-10.71" spread="11.012"/>
                    <measurement group_id="O15" value="-12.46" spread="8.763"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 6 in Mean SBP and DBP Measured in Afternoon by 24hr ABPM</title>
        <description>Mean changes from Baseline to Week 6 in SBP and DBP measured by 24hr ABPM at the end of up-titration recorded in the afternoon. The afternoon assessment period started at or after 12 noon and ended immediately before 6 pm.</description>
        <time_frame>Afternoon BP, Baseline, Week 6</time_frame>
        <population>ABPM Population with LOCF: This comprised all randomized subjects with efficacy (vital signs) data after a minimum of 2 weeks on treatment with valid Baseline and on-therapy ABPM measures. All efficacy data derived from ABPM assessments were summarized by this population</population>
        <group_list>
          <group group_id="O1">
            <title>Lisinopril 10</title>
            <description>lisinopril 10 milligrams (mg) once daily</description>
          </group>
          <group group_id="O2">
            <title>Lisinopril 20</title>
            <description>lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Lisinopril 40</title>
            <description>lisinopril 40 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Carvedilol Controlled Release 20</title>
            <description>carvedilol controlled release (CR) 20 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Carvedilol Controlled Release 40</title>
            <description>carvedilol CR 40 mg once daily</description>
          </group>
          <group group_id="O6">
            <title>Carvedilol Controlled Release 80</title>
            <description>carvedilol CR 80 mg once daily</description>
          </group>
          <group group_id="O7">
            <title>Carvedilol Controlled Release 20 Lisinopril 10</title>
            <description>carvedilol CR 20 mg plus lisinopril 10 mg once daily</description>
          </group>
          <group group_id="O8">
            <title>Carvedilol Controlled Release 20 Lisinopril 20</title>
            <description>carvedilol CR 20 mg plus lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O9">
            <title>Carvedilol Controlled Release 20 Lisinopril 40</title>
            <description>carvedilol CR 20 mg plus lisinopril 40 mg once daily</description>
          </group>
          <group group_id="O10">
            <title>Carvedilol Controlled Release 40 Lisinopril 10</title>
            <description>carvedilol CR 40 mg plus lisinopril 10 mg once daily</description>
          </group>
          <group group_id="O11">
            <title>Carvedilol Controlled Release 40 Lisinopril 20</title>
            <description>carvedilol CR 40 mg plus lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O12">
            <title>Carvedilol Controlled Release 40 Lisinopril 40</title>
            <description>carvedilol CR 40 mg plus lisinopril 40 mg once daily</description>
          </group>
          <group group_id="O13">
            <title>Carvedilol Controlled Release 80 Lisinopril 10</title>
            <description>carvedilol CR 80 mg plus lisinopril 10 mg once daily</description>
          </group>
          <group group_id="O14">
            <title>Carvedilol Controlled Release 80 Lisinopril 20</title>
            <description>carvedilol CR 80 mg plus lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O15">
            <title>Carvedilol Controlled Release 80 Lisinopril 40</title>
            <description>carvedilol CR 80 mg plus lisinopril 40 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 6 in Mean SBP and DBP Measured in Afternoon by 24hr ABPM</title>
          <description>Mean changes from Baseline to Week 6 in SBP and DBP measured by 24hr ABPM at the end of up-titration recorded in the afternoon. The afternoon assessment period started at or after 12 noon and ended immediately before 6 pm.</description>
          <population>ABPM Population with LOCF: This comprised all randomized subjects with efficacy (vital signs) data after a minimum of 2 weeks on treatment with valid Baseline and on-therapy ABPM measures. All efficacy data derived from ABPM assessments were summarized by this population</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="35"/>
                <count group_id="O8" value="37"/>
                <count group_id="O9" value="34"/>
                <count group_id="O10" value="32"/>
                <count group_id="O11" value="35"/>
                <count group_id="O12" value="34"/>
                <count group_id="O13" value="28"/>
                <count group_id="O14" value="33"/>
                <count group_id="O15" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in Afternoon SBP from Baseline to Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.68" spread="11.399"/>
                    <measurement group_id="O2" value="-17.21" spread="19.772"/>
                    <measurement group_id="O3" value="-10.53" spread="13.359"/>
                    <measurement group_id="O4" value="-9.69" spread="10.094"/>
                    <measurement group_id="O5" value="-13.34" spread="9.669"/>
                    <measurement group_id="O6" value="-13.76" spread="11.796"/>
                    <measurement group_id="O7" value="-13.96" spread="13.128"/>
                    <measurement group_id="O8" value="-15.54" spread="13.503"/>
                    <measurement group_id="O9" value="-16.38" spread="13.285"/>
                    <measurement group_id="O10" value="-14.51" spread="13.433"/>
                    <measurement group_id="O11" value="-17.97" spread="14.622"/>
                    <measurement group_id="O12" value="-17.82" spread="13.042"/>
                    <measurement group_id="O13" value="-20.91" spread="13.704"/>
                    <measurement group_id="O14" value="-20.46" spread="17.611"/>
                    <measurement group_id="O15" value="-19.36" spread="14.893"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Afternoon DBP from Baseline to Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.62" spread="7.969"/>
                    <measurement group_id="O2" value="-10.25" spread="12.250"/>
                    <measurement group_id="O3" value="-6.67" spread="7.800"/>
                    <measurement group_id="O4" value="-6.27" spread="8.910"/>
                    <measurement group_id="O5" value="-10.12" spread="6.555"/>
                    <measurement group_id="O6" value="-8.38" spread="7.787"/>
                    <measurement group_id="O7" value="-11.28" spread="8.998"/>
                    <measurement group_id="O8" value="-12.04" spread="8.132"/>
                    <measurement group_id="O9" value="-11.59" spread="10.112"/>
                    <measurement group_id="O10" value="-12.18" spread="9.905"/>
                    <measurement group_id="O11" value="-14.03" spread="9.425"/>
                    <measurement group_id="O12" value="-12.54" spread="8.893"/>
                    <measurement group_id="O13" value="-15.12" spread="8.437"/>
                    <measurement group_id="O14" value="-13.87" spread="12.997"/>
                    <measurement group_id="O15" value="-15.02" spread="9.197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 6 in Mean SBP and DBP Measured at Night by 24hr ABPM</title>
        <description>Mean changes from Baseline to Week 6 in DBP and SBP measured by 24hr ABPM at the end of up-titration recorded in the night. The night-time assessment period started at the time of the first reading at or after 6 pm and ended immediately before 6 am on the following day.</description>
        <time_frame>Night BP, Baseline, Week 6</time_frame>
        <population>: ABPM Population with LOCF: This comprised all randomized subjects with efficacy (vital signs) data after a minimum of 2 weeks on treatment with valid Baseline and on-therapy ABPM measures. All efficacy data derived from ABPM assessments were summarized by this population</population>
        <group_list>
          <group group_id="O1">
            <title>Lisinopril 10</title>
            <description>lisinopril 10 milligrams (mg) once daily</description>
          </group>
          <group group_id="O2">
            <title>Lisinopril 20</title>
            <description>lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Lisinopril 40</title>
            <description>lisinopril 40 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Carvedilol Controlled Release 20</title>
            <description>carvedilol controlled release (CR) 20 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Carvedilol Controlled Release 40</title>
            <description>carvedilol CR 40 mg once daily</description>
          </group>
          <group group_id="O6">
            <title>Carvedilol Controlled Release 80</title>
            <description>carvedilol CR 80 mg once daily</description>
          </group>
          <group group_id="O7">
            <title>Carvedilol Controlled Release 20 Lisinopril 10</title>
            <description>carvedilol CR 20 mg plus lisinopril 10 mg once daily</description>
          </group>
          <group group_id="O8">
            <title>Carvedilol Controlled Release 20 Lisinopril 20</title>
            <description>carvedilol CR 20 mg plus lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O9">
            <title>Carvedilol Controlled Release 20 Lisinopril 40</title>
            <description>carvedilol CR 20 mg plus lisinopril 40 mg once daily</description>
          </group>
          <group group_id="O10">
            <title>Carvedilol Controlled Release 40 Lisinopril 10</title>
            <description>carvedilol CR 40 mg plus lisinopril 10 mg once daily</description>
          </group>
          <group group_id="O11">
            <title>Carvedilol Controlled Release 40 Lisinopril 20</title>
            <description>carvedilol CR 40 mg plus lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O12">
            <title>Carvedilol Controlled Release 40 Lisinopril 40</title>
            <description>carvedilol CR 40 mg plus lisinopril 40 mg once daily</description>
          </group>
          <group group_id="O13">
            <title>Carvedilol Controlled Release 80 Lisinopril 10</title>
            <description>carvedilol CR 80 mg plus lisinopril 10 mg once daily</description>
          </group>
          <group group_id="O14">
            <title>Carvedilol Controlled Release 80 Lisinopril 20</title>
            <description>carvedilol CR 80 mg plus lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O15">
            <title>Carvedilol Controlled Release 80 Lisinopril 40</title>
            <description>carvedilol CR 80 mg plus lisinopril 40 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 6 in Mean SBP and DBP Measured at Night by 24hr ABPM</title>
          <description>Mean changes from Baseline to Week 6 in DBP and SBP measured by 24hr ABPM at the end of up-titration recorded in the night. The night-time assessment period started at the time of the first reading at or after 6 pm and ended immediately before 6 am on the following day.</description>
          <population>: ABPM Population with LOCF: This comprised all randomized subjects with efficacy (vital signs) data after a minimum of 2 weeks on treatment with valid Baseline and on-therapy ABPM measures. All efficacy data derived from ABPM assessments were summarized by this population</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="38"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="35"/>
                <count group_id="O8" value="37"/>
                <count group_id="O9" value="34"/>
                <count group_id="O10" value="32"/>
                <count group_id="O11" value="35"/>
                <count group_id="O12" value="34"/>
                <count group_id="O13" value="28"/>
                <count group_id="O14" value="33"/>
                <count group_id="O15" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in Night SBP from Baseline to Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.01" spread="10.635"/>
                    <measurement group_id="O2" value="-11.58" spread="16.103"/>
                    <measurement group_id="O3" value="-10.38" spread="8.600"/>
                    <measurement group_id="O4" value="-4.28" spread="8.018"/>
                    <measurement group_id="O5" value="-7.70" spread="10.178"/>
                    <measurement group_id="O6" value="-7.71" spread="9.627"/>
                    <measurement group_id="O7" value="-10.37" spread="11.517"/>
                    <measurement group_id="O8" value="-9.94" spread="11.220"/>
                    <measurement group_id="O9" value="-12.64" spread="11.301"/>
                    <measurement group_id="O10" value="-10.02" spread="10.256"/>
                    <measurement group_id="O11" value="-11.87" spread="12.031"/>
                    <measurement group_id="O12" value="-11.25" spread="11.462"/>
                    <measurement group_id="O13" value="-12.08" spread="9.486"/>
                    <measurement group_id="O14" value="-14.12" spread="12.151"/>
                    <measurement group_id="O15" value="-13.06" spread="10.651"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in Night DBP from Baseline to Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.83" spread="6.602"/>
                    <measurement group_id="O2" value="-6.78" spread="8.251"/>
                    <measurement group_id="O3" value="-7.49" spread="6.085"/>
                    <measurement group_id="O4" value="-3.20" spread="5.340"/>
                    <measurement group_id="O5" value="-6.49" spread="5.723"/>
                    <measurement group_id="O6" value="-5.34" spread="7.187"/>
                    <measurement group_id="O7" value="-8.11" spread="7.260"/>
                    <measurement group_id="O8" value="-7.03" spread="6.853"/>
                    <measurement group_id="O9" value="-9.36" spread="7.068"/>
                    <measurement group_id="O10" value="-8.23" spread="7.458"/>
                    <measurement group_id="O11" value="-9.34" spread="8.960"/>
                    <measurement group_id="O12" value="-9.09" spread="7.321"/>
                    <measurement group_id="O13" value="-8.27" spread="6.002"/>
                    <measurement group_id="O14" value="-9.88" spread="8.161"/>
                    <measurement group_id="O15" value="-10.14" spread="7.468"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 6 in Mean Trough Sitting SBP and Sitting DBP by Cuff Assessment</title>
        <description>Analysis of Change from Baseline to Week 6 in Mean sSBP and sDBP by Cuff Assessments at Drug Trough (20-24 hr) at End of Treatment Titration</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>ITTE with LOCF. Intent to Treat Efficacy population is defined as all randomized subjects with efficacy (vital signs) data after a minimum of 2 weeks on treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Lisinopril 10</title>
            <description>lisinopril 10 milligrams (mg) once daily</description>
          </group>
          <group group_id="O2">
            <title>Lisinopril 20</title>
            <description>lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Lisinopril 40</title>
            <description>lisinopril 40 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Carvedilol Controlled Release 20</title>
            <description>carvedilol controlled release (CR) 20 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Carvedilol Controlled Release 40</title>
            <description>carvedilol CR 40 mg once daily</description>
          </group>
          <group group_id="O6">
            <title>Carvedilol Controlled Release 80</title>
            <description>carvedilol CR 80 mg once daily</description>
          </group>
          <group group_id="O7">
            <title>Carvedilol Controlled Release 20 Lisinopril 10</title>
            <description>carvedilol CR 20 mg plus lisinopril 10 mg once daily</description>
          </group>
          <group group_id="O8">
            <title>Carvedilol Controlled Release 20 Lisinopril 20</title>
            <description>carvedilol CR 20 mg plus lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O9">
            <title>Carvedilol Controlled Release 20 Lisinopril 40</title>
            <description>carvedilol CR 20 mg plus lisinopril 40 mg once daily</description>
          </group>
          <group group_id="O10">
            <title>Carvedilol Controlled Release 40 Lisinopril 10</title>
            <description>carvedilol CR 40 mg plus lisinopril 10 mg once daily</description>
          </group>
          <group group_id="O11">
            <title>Carvedilol Controlled Release 40 Lisinopril 20</title>
            <description>carvedilol CR 40 mg plus lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O12">
            <title>Carvedilol Controlled Release 40 Lisinopril 40</title>
            <description>carvedilol CR 40 mg plus lisinopril 40 mg once daily</description>
          </group>
          <group group_id="O13">
            <title>Carvedilol Controlled Release 80 Lisinopril 10</title>
            <description>carvedilol CR 80 mg plus lisinopril 10 mg once daily</description>
          </group>
          <group group_id="O14">
            <title>Carvedilol Controlled Release 80 Lisinopril 20</title>
            <description>carvedilol CR 80 mg plus lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O15">
            <title>Carvedilol Controlled Release 80 Lisinopril 40</title>
            <description>carvedilol CR 80 mg plus lisinopril 40 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 6 in Mean Trough Sitting SBP and Sitting DBP by Cuff Assessment</title>
          <description>Analysis of Change from Baseline to Week 6 in Mean sSBP and sDBP by Cuff Assessments at Drug Trough (20-24 hr) at End of Treatment Titration</description>
          <population>ITTE with LOCF. Intent to Treat Efficacy population is defined as all randomized subjects with efficacy (vital signs) data after a minimum of 2 weeks on treatment.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="41"/>
                <count group_id="O8" value="42"/>
                <count group_id="O9" value="43"/>
                <count group_id="O10" value="42"/>
                <count group_id="O11" value="43"/>
                <count group_id="O12" value="40"/>
                <count group_id="O13" value="39"/>
                <count group_id="O14" value="43"/>
                <count group_id="O15" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in sSBP by Cuff from Baseline to Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.97" spread="13.671"/>
                    <measurement group_id="O2" value="-10.85" spread="12.975"/>
                    <measurement group_id="O3" value="-13.09" spread="10.200"/>
                    <measurement group_id="O4" value="-5.68" spread="10.074"/>
                    <measurement group_id="O5" value="-5.07" spread="15.610"/>
                    <measurement group_id="O6" value="-8.88" spread="15.179"/>
                    <measurement group_id="O7" value="-9.54" spread="14.373"/>
                    <measurement group_id="O8" value="-11.84" spread="16.943"/>
                    <measurement group_id="O9" value="-13.43" spread="15.279"/>
                    <measurement group_id="O10" value="-9.79" spread="14.481"/>
                    <measurement group_id="O11" value="-11.26" spread="15.056"/>
                    <measurement group_id="O12" value="-13.49" spread="17.626"/>
                    <measurement group_id="O13" value="-6.42" spread="16.409"/>
                    <measurement group_id="O14" value="-9.00" spread="14.541"/>
                    <measurement group_id="O15" value="-14.58" spread="16.176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in sDBP by Cuff from Baseline to Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.45" spread="13.671"/>
                    <measurement group_id="O2" value="-5.32" spread="8.969"/>
                    <measurement group_id="O3" value="-10.35" spread="7.627"/>
                    <measurement group_id="O4" value="-6.87" spread="5.671"/>
                    <measurement group_id="O5" value="-5.70" spread="9.760"/>
                    <measurement group_id="O6" value="-7.54" spread="8.469"/>
                    <measurement group_id="O7" value="-5.66" spread="8.949"/>
                    <measurement group_id="O8" value="-10.02" spread="10.384"/>
                    <measurement group_id="O9" value="-10.28" spread="8.543"/>
                    <measurement group_id="O10" value="-8.73" spread="10.771"/>
                    <measurement group_id="O11" value="-10.89" spread="10.757"/>
                    <measurement group_id="O12" value="-9.63" spread="11.073"/>
                    <measurement group_id="O13" value="-8.22" spread="9.203"/>
                    <measurement group_id="O14" value="-9.45" spread="11.204"/>
                    <measurement group_id="O15" value="-10.95" spread="8.624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Responders, Defined as â‰¥ 10 mmHg Sitting (s)DBP Reduction From Baseline or a sDBP of &lt;90 / 80 Millimeters (mm) of Mercury (Hg) for Non Diabetic / Diabetic Subjects Respectively (Based on Cuff Trough Measures)</title>
        <time_frame>Week 6</time_frame>
        <population>ITTE with LOCF. Intent to Treat Efficacy population is defined as all randomized subjects with efficacy (vital signs) data after a minimum of 2 weeks on treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Lisinopril 10</title>
            <description>lisinopril 10 milligrams (mg) once daily</description>
          </group>
          <group group_id="O2">
            <title>Lisinopril 20</title>
            <description>lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Lisinopril 40</title>
            <description>lisinopril 40 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>Carvedilol Controlled Release 20</title>
            <description>carvedilol controlled release (CR) 20 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Carvedilol Controlled Release 40</title>
            <description>carvedilol CR 40 mg once daily</description>
          </group>
          <group group_id="O6">
            <title>Carvedilol Controlled Release 80</title>
            <description>carvedilol CR 80 mg once daily</description>
          </group>
          <group group_id="O7">
            <title>Carvedilol Controlled Release 20 Lisinopril 10</title>
            <description>carvedilol CR 20 mg plus lisinopril 10 mg once daily</description>
          </group>
          <group group_id="O8">
            <title>Carvedilol Controlled Release 20 Lisinopril 20</title>
            <description>carvedilol CR 20 mg plus lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O9">
            <title>Carvedilol Controlled Release 20 Lisinopril 40</title>
            <description>carvedilol CR 20 mg plus lisinopril 40 mg once daily</description>
          </group>
          <group group_id="O10">
            <title>Carvedilol Controlled Release 40 Lisinopril 10</title>
            <description>carvedilol CR 40 mg plus lisinopril 10 mg once daily</description>
          </group>
          <group group_id="O11">
            <title>Carvedilol Controlled Release 40 Lisinopril 20</title>
            <description>carvedilol CR 40 mg plus lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O12">
            <title>Carvedilol Controlled Release 40 Lisinopril 40</title>
            <description>carvedilol CR 40 mg plus lisinopril 40 mg once daily</description>
          </group>
          <group group_id="O13">
            <title>Carvedilol Controlled Release 80 Lisinopril 10</title>
            <description>carvedilol CR 80 mg plus lisinopril 10 mg once daily</description>
          </group>
          <group group_id="O14">
            <title>Carvedilol Controlled Release 80 Lisinopril 20</title>
            <description>carvedilol CR 80 mg plus lisinopril 20 mg once daily</description>
          </group>
          <group group_id="O15">
            <title>Carvedilol Controlled Release 80 Lisinopril 40</title>
            <description>carvedilol CR 80 mg plus lisinopril 40 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Responders, Defined as â‰¥ 10 mmHg Sitting (s)DBP Reduction From Baseline or a sDBP of &lt;90 / 80 Millimeters (mm) of Mercury (Hg) for Non Diabetic / Diabetic Subjects Respectively (Based on Cuff Trough Measures)</title>
          <population>ITTE with LOCF. Intent to Treat Efficacy population is defined as all randomized subjects with efficacy (vital signs) data after a minimum of 2 weeks on treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="41"/>
                <count group_id="O8" value="42"/>
                <count group_id="O9" value="43"/>
                <count group_id="O10" value="42"/>
                <count group_id="O11" value="43"/>
                <count group_id="O12" value="40"/>
                <count group_id="O13" value="39"/>
                <count group_id="O14" value="43"/>
                <count group_id="O15" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="17"/>
                    <measurement group_id="O7" value="20"/>
                    <measurement group_id="O8" value="28"/>
                    <measurement group_id="O9" value="25"/>
                    <measurement group_id="O10" value="30"/>
                    <measurement group_id="O11" value="22"/>
                    <measurement group_id="O12" value="27"/>
                    <measurement group_id="O13" value="28"/>
                    <measurement group_id="O14" value="24"/>
                    <measurement group_id="O15" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>SAE/AE summary is based on the safety population, which comprised all randomized participants who received at least one dose of study medication; thus, the number of participants at risk differs by 1 for the Lis 20, Carv 40, Carv 40/Lis 40, and Carv 80/40 groups between the AE/SAE summary and the Participant Flow (all randomized participants).</desc>
      <group_list>
        <group group_id="E1">
          <title>Lisinopril 10</title>
          <description>lisinopril 10 milligrams (mg) once daily</description>
        </group>
        <group group_id="E2">
          <title>Lisinopril 20</title>
          <description>lisinopril 20 mg once daily</description>
        </group>
        <group group_id="E3">
          <title>Lisinopril 40</title>
          <description>lisinopril 40 mg once daily</description>
        </group>
        <group group_id="E4">
          <title>Carvedilol Controlled Release 20</title>
          <description>carvedilol controlled release (CR) 20 mg once daily</description>
        </group>
        <group group_id="E5">
          <title>Carvedilol Controlled Release 40</title>
          <description>carvedilol CR 40 mg once daily</description>
        </group>
        <group group_id="E6">
          <title>Carvedilol Controlled Release 80</title>
          <description>carvedilol CR 80 mg once daily</description>
        </group>
        <group group_id="E7">
          <title>Carvedilol Controlled Release 20 Lisinopril 10</title>
          <description>carvedilol CR 20 mg plus lisinopril 10 mg once daily</description>
        </group>
        <group group_id="E8">
          <title>Carvedilol Controlled Release 20 Lisinopril 20</title>
          <description>carvedilol CR 20 mg plus lisinopril 20 mg once daily</description>
        </group>
        <group group_id="E9">
          <title>Carvedilol Controlled Release 20 Lisinopril 40</title>
          <description>carvedilol CR 20 mg plus lisinopril 40 mg once daily</description>
        </group>
        <group group_id="E10">
          <title>Carvedilol Controlled Release 40 Lisinopril 10</title>
          <description>carvedilol CR 40 mg plus lisinopril 10 mg once daily</description>
        </group>
        <group group_id="E11">
          <title>Carvedilol Controlled Release 40 Lisinopril 20</title>
          <description>carvedilol CR 40 mg plus lisinopril 20 mg once daily</description>
        </group>
        <group group_id="E12">
          <title>Carvedilol Controlled Release 40 Lisinopril 40</title>
          <description>carvedilol CR 40 mg plus lisinopril 40 mg once daily</description>
        </group>
        <group group_id="E13">
          <title>Carvedilol Controlled Release 80 Lisinopril 10</title>
          <description>carvedilol CR 80 mg plus lisinopril 10 mg once daily</description>
        </group>
        <group group_id="E14">
          <title>Carvedilol Controlled Release 80 Lisinopril 20</title>
          <description>carvedilol CR 80 mg plus lisinopril 20 mg once daily</description>
        </group>
        <group group_id="E15">
          <title>Carvedilol Controlled Release 80 Lisinopril 40</title>
          <description>carvedilol CR 80 mg plus lisinopril 40 mg once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0"/>
                <counts group_id="E2" subjects_affected="1"/>
                <counts group_id="E3" subjects_affected="0"/>
                <counts group_id="E4" subjects_affected="2"/>
                <counts group_id="E5" subjects_affected="0"/>
                <counts group_id="E6" subjects_affected="0"/>
                <counts group_id="E7" subjects_affected="0"/>
                <counts group_id="E8" subjects_affected="1"/>
                <counts group_id="E9" subjects_affected="2"/>
                <counts group_id="E10" subjects_affected="1"/>
                <counts group_id="E11" subjects_affected="3"/>
                <counts group_id="E12" subjects_affected="0"/>
                <counts group_id="E13" subjects_affected="1"/>
                <counts group_id="E14" subjects_affected="1"/>
                <counts group_id="E15" subjects_affected="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Left bundle branch block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cervical vertebral fracture (C2)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Listless</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension (worsening)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22"/>
                <counts group_id="E2" subjects_affected="15"/>
                <counts group_id="E3" subjects_affected="21"/>
                <counts group_id="E4" subjects_affected="20"/>
                <counts group_id="E5" subjects_affected="17"/>
                <counts group_id="E6" subjects_affected="13"/>
                <counts group_id="E7" subjects_affected="19"/>
                <counts group_id="E8" subjects_affected="20"/>
                <counts group_id="E9" subjects_affected="30"/>
                <counts group_id="E10" subjects_affected="21"/>
                <counts group_id="E11" subjects_affected="33"/>
                <counts group_id="E12" subjects_affected="19"/>
                <counts group_id="E13" subjects_affected="13"/>
                <counts group_id="E14" subjects_affected="38"/>
                <counts group_id="E15" subjects_affected="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the Publication of results from all centers of a multi-center trial but requests that reports based on Single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

